Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: ECE (Ecklonia cava extract)Dietary Supplement: Placebo
- Registration Number
- NCT02091024
- Lead Sponsor
- Chonbuk National University Hospital
- Brief Summary
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia.
- Detailed Description
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia. The investigators measured improvement of lipid profile, including total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Mild hypercholesterolemic subjects(≥200mg/dL of total cholesterol or ≥110mg/dL of LDL-cholesterol)
Exclusion Criteria
- Self-reported pregnancy, lactation
- Prevalent heart disease, cancer, renal disorder, or diabetes mellitus, and use of lipid-lowering drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ECG (Ecklonia cava extract) ECE (Ecklonia cava extract) ECE 200mg, twice a day Placebo Placebo Placebo 200mg, twice a day
- Primary Outcome Measures
Name Time Method Changes in total cholesterol 12 weeks Changes in LDL-cholesterol 12 weeks
- Secondary Outcome Measures
Name Time Method Changes in triglyceride 12 weeks Changes in HDL-cholesterol 12 weeks Changes in waist to hip ratio 12 weeks
Trial Locations
- Locations (1)
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
🇰🇷Jeonju, Jeollabuk-do, Korea, Republic of